louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06902948: Effectiveness of a Standardized Stroke Upper Limb Rehabilitation Program with Shortened Fugl-Meyer Assessment Stratification
Official title: Effectiveness of a Standardized Stroke Upper Limb Rehabilitation Program with Shortened Fugl-Meyer Assessment Stratification: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Keywords: Shortened Fugl-Meyer Assessment
stroke rehabilitation
upper limb
Lead sponsor: Tai Po Hospital
Sponsor class: OTHER_GOV
First posted: 2025-03-30
Enrollment: 44
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the study was to investigate the effectiveness of a standardized stroke upper limb rehabilitation program with stratification using Shortened Fugl-Meyer Assessment (S-FM). The standardized program was compared with conventional training based on the hospital protocol.


Eligibility criteria: Inclusion Criteria:

* first stroke, able to attend gym training and give written consent

Exclusion Criteria:

* unstable medical condition, any musculoskeletal conditions or other diseases restricted upper limb training, unfit mental state and unable to follow command

Primary outcomes:
measure: Shortened Fugl-Meyer Assessment (S-FM)
timeFrame: From enrollment to the end of treatment up to 6 weeks
measure: Functional Test for the Hemiplegic Upper Extremity (FTHUE)
timeFrame: From enrollment to the end of treatment up to 6 weeks
Secondary outcomes:
measure: Modified Barthel Index (MBI)
timeFrame: From enrollment to the end of treatment up to 6 weeks
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Tai Po Hospital
Study officials:
References:
citation: McDonnell MN, Hillier SL, Esterman AJ. Standardizing the approach to evidence-based upper limb rehabilitation after stroke. Top Stroke Rehabil. 2013 Sep-Oct;20(5):432-40. doi: 10.1310/tsr2005-432.
citation: Garcia-Vega J, Gregory G, Lind CRP, Singer BJ. Development of a consensus approach to upper limb rehabilitation early post stroke amongst a cohort of Western Australian therapists. N Z J Physiother 2016;44(3):133-147
citation: Hirayama K, Takebayashi T, Takahashi K. Factors Influencing Decision-Making for Poststroke Paretic Upper Limb Treatment: A Survey of Japanese Physical and Occupational Therapists. Occup Ther Int. 2024 Oct 7;2024:1854449. doi: 10.1155/2024/1854449. eCollection 2024.
citation: Hsieh YW, Hsueh IP, Chou YT, Sheu CF, Hsieh CL, Kwakkel G. Development and validation of a short form of the Fugl-Meyer motor scale in patients with stroke. Stroke. 2007 Nov;38(11):3052-4. doi: 10.1161/STROKEAHA.107.490730. Epub 2007 Oct 4.
Clinical trial NCT05184348: Plexin B2 Gene Expression and Polymorphisms in Psoriasis
Official title: Plexin B2 Gene Expression and Polymorphisms in Psoriasis : Relation to NB-UVB, Acitretin and Combined Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Psoriasis Vulgaris
Lead sponsor: South Valley University
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 200
Sex: ALL
Minimum age (years): 24
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients will be randomly assigned (1:1:1 ) either to ; NB-UVB photo-therapy alone , Acitretin therapy alone or NB-UVB photo-therapy combined with Acitretin therapy randomization will be done by closed envelopes . investigator will be blinded to study drug assignment , while patients and data interpreter will not be masked to study drug assignment.

Detailed description: Study Setting: Qena University Hospital, Department of Dermatology ,Venereology\& Andrology.

Study subjects: the study will include psoriasis Vulgaris patients who Come to the out patients dermatologic clinic and matching inclusion \& exclusion criteria as follow, from 9/2021 up to 3/2023 and then patients will be divided to each group equally as follow:

Group 1: Patients will be treated with NB-UVB phototherapy 3 sessions weekly for 3 months with maximum dose of 1400 mJ/cm2.

Group 2: Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally for 3 months Group 3: Patients will be treated with Acitretin in dose of 0.5-1 mg per kg per day orally plus NB-UVB phototherapy 3 sessions weekly for 3 months with maximum dose 1400 mJ/cm2.

Group 4: 30 healthy individuals un related , age, sex , BMI matched with volunteers.

Eligibility criteria: Inclusion Criteria:

* Patients of both sexes. Diagnosed clinically with moderate to severe Psoriasis Vulgaris.
* patients able to swallow tablet and receive Narrow band Ultraviolet B phototherapy without any contraindication

Exclusion Criteria:

Pregnancy , lactation \& women intent to become pregnant within 3 year after discontinuation of acitretin Patients with Hyperlipidemia Patients with mental problems and depression Patients with a history of malignancies, renal \& liver diseases. Patients with a history of any inflammatory diseases as atopic dermatitis , asthma ulcerative colitis ) and Crohn's disease Patients received NB-UVB phototherapy in the last 6 months. Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.

Primary outcomes:
measure: Improve the prognosis of patients with psoriasis Vulgaris
timeFrame: 3 month
Secondary outcomes:
measure: Improve the clinical out comes of patients with psoriasis Vulgaris
timeFrame: 12 month
Other outcomes:
Locations:
city: Qina
country: Egypt
facility: Faculty of Medicine , South Valley University
Study officials:
affiliation: Faculty of Medicine, South Valley University, Egypt
name: Eisa Hegazy, Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT02053948: Pursestring Wound Closure vs "Gunsight" Skin Incision and Closure Technique to Reverse Stoma
Official title: Randomized Clinical Trial of Stoma Reversal Comparing Pursestring Wound Closure vs "Gunsight" Skin Incision and Closure Technique to Eliminate the Risk of Wound Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colostomy
Keywords: Reversal
Surgical technique
Pursestring Wound Closure
Gunsight Skin Incision and Closure Technique
Lead sponsor: Beijing Chao Yang Hospital
Sponsor class: OTHER
Collaborators: name: Beijing Friendship Hospital
name: Shengjing Hospital
name: Hebei Medical University Fourth Hospital
name: Sixth Affiliated Hospital, Sun Yat-sen University
name: Peking University People's Hospital
name: Peking Union Medical College Hospital
name: Chinese PLA General Hospital
name: Jinling Hospital, China
name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
name: First Hospital of China Medical University
First posted: 2014-02-04
Enrollment: 143
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The use of temporary stomas has been demonstrated to reduce septic complications after colorectal cancer surgery, especially in high-risk anastomosis; therefore, it is necessary to reduce the number of complications secondary to ostomy takedowns, namely wound infection. The aim of this study is to compare the rates of superficial wound infection, healing time and patient satisfaction after pursestring closure vs "gunsight" skin incision and closure technique closure.


Eligibility criteria: Inclusion Criteria:

* loop colostomy
* end colostomy

Exclusion Criteria:

* other stomy

Primary outcomes:
measure: superficial wound infection of stoma site
timeFrame: 1 year
Secondary outcomes:
measure: Healing time after stoma reversal
timeFrame: 1 year
Other outcomes:
measure: Patient's satisfaction about the wound after stoma reversal
timeFrame: 1 year
Locations:
city: Beijing
country: China
facility: Beijing Chaoyang Hospital
state: Beijing
Study officials:
affiliation: Beijing Chao Yang Hospital
name: Jiagang Han, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Camacho-Mauries D, Rodriguez-Diaz JL, Salgado-Nesme N, Gonzalez QH, Vergara-Fernandez O. Randomized clinical trial of intestinal ostomy takedown comparing pursestring wound closure vs conventional closure to eliminate the risk of wound infection. Dis Colon Rectum. 2013 Feb;56(2):205-11. doi: 10.1097/DCR.0b013e31827888f6.
citation: Lim JT, Shedda SM, Hayes IP. "Gunsight" skin incision and closure technique for stoma reversal. Dis Colon Rectum. 2010 Nov;53(11):1569-75. doi: 10.1007/DCR.0b013e3181f0535a.
citation: Han JG, Yao HW, Zhou JP, Zhang H, Wang GY, Shen ZL, Gong JF, Wang ZJ; Colorectal Surgery Group of Chinese Academic Society of Young Surgeons. Gunsight Procedure Versus the Purse-String Procedure for Closing Wounds After Stoma Reversal: A Multicenter Prospective Randomized Trial. Dis Colon Rectum. 2020 Oct;63(10):1411-1418. doi: 10.1097/DCR.0000000000001755.
Clinical trial NCT02182648: Bispectral Index Guiding Etomidate Used in Children Aged 3 to 10 for Clinical Anesthesia Induction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Bispectral Index
Pediatric
Etomidate
Induction
Lead sponsor: Henan Provincial People's Hospital
Sponsor class: OTHER
First posted: 2014-07-08
Enrollment: 120
Sex: ALL
Minimum age (years): 3
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research through using bispectral index to guide the induced dose and speed of etomidate lipid emulsion for pediatric total venous anesthesia,and to provide a reference for clinical anesthesia physician.


Eligibility criteria: Inclusion Criteria:

1. obtain informed consent;
2. undergoing elective hypospadias repair surgery under general anesthesia;
3. American society of anesthesiologists (ASA) class I-II;
4. aged between 3-10 years old;
5. BMI is 18.5-30 kg/m2;

Exclusion Criteria:

1. systolic blood pressure≥180 mmHg or\<90 mmHg, diastolic blood pressure≥110 mmHg or\<60 mmHg;
2. serious heart, brain, liver, kidney, lung, endocrine diseases or serious infections;
3. long-term use of hormone or a history of adrenal cortex inhibition;
4. suspected or confirmed difficult airway;
5. suspected or confirmed abuse of narcotic analgesic drugs, psychotropic drugs;
6. neuromuscular disease;
7. mental instability, or have a mental illness;
8. allergic to investigational products or with other contraindication
9. participated in other study within 30 days

Primary outcomes:
measure: the amount of drugs
timeFrame: from the beginning of induction to Bispectral Index < 50,up to 5 minutes
measure: the drugs used time
timeFrame: from the beginning of induction to Bispectral Index < 50,expected to be within 1 minute
measure: numbers of muscular fibrillation
timeFrame: from the beginning of induction to Bispectral Index < 50,up to 5 minutes
measure: degree of inflammation reaction
timeFrame: baseline,5 minutes after indution,5 minutes before operation end,30 mimutes、24h and 48h after operation
measure: adrenal function
timeFrame: baseline,5 minutes after indution,5 minutes before operation end,30 mimutes、24h and 48h after operation
Secondary outcomes:
measure: hemodynamic parameters
timeFrame: from the beginning of induction to skin closure, up to 3 hours
measure: sedation degree
timeFrame: from the beginning of induction to skin closure, up to 3 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01708148: Oral Administration of Four Lactobacillus Species Preparation to Improve the Quality of the Neovaginal Flora in Male to Female Transsexual Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Reduction or Absence of Lactobacilli in Neovaginal Flora
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
Collaborators: name: University of Natural Resources and Life Sciences, Vienna, Austria
First posted: 2012-10-16
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is the improvement of the penile linked neovaginal flora in male-to-female transsexuals after application of oral probiotics.


Eligibility criteria: Inclusion Criteria:

Participants underwent the sex reassignment surgery (SRS) with the technique of the inverted penile skin flap longer than 1 year.

All transsexual women treated according to the Standards of Care of the World Professional Association of Transgender Health (WPATH).

Exclusion Criteria:

* clinical signs of vaginal or urinary tract infection,
* abnormal neovaginal discharge,
* neoplasia,
* bleeding,
* diarrhoea,
* constipation,
* rectal pathologies including hemorrhoids,
* antibiotic therapy in the previous 4 weeks

Primary outcomes:
measure: change in Nugent score between baseline and end of treatment (improvement or no improvement).
timeFrame: day 0 day 7 of oral probiotic application
Secondary outcomes:
measure: Isolation of specific Lactobacilli from neovaginal microbiologic cultures after oral administration of probiotic
timeFrame: Day 7 of oral probiotic application
Other outcomes:
measure: Nugent Score
timeFrame: day 0 day 7 of oral probiotic application
Locations:
city: Vienna
country: Austria
facility: Department of Obstetrics and Gyecology, AKH
Study officials:
References:
Clinical trial NCT06415448: Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema
Official title: Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema (HAE)
Study type: EXPANDED_ACCESS
Overall status: AVAILABLE
Conditions: Hereditary Angioedema
Keywords: HAE
IONIS PKK-LRx
Donidalorsen
ISIS 721744
Lead sponsor: Ionis Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2024-05-16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT

Brief summary: The purpose of the Expanded Access Program is to provide pre-approval access of donidalorsen to eligible patients with Hereditary Angioedema (HAE) who complete the ISIS 721744-CS3 clinical trial.

Detailed description: The Expanded Access Program (EAP) is intended to provide pre-approval access to donidalorsen for eligible patients with HAE who complete the ISIS 721744-CS3 clinical trial.

Eligibility criteria: Inclusion Criteria:

* Patients in the ISIS 721744-CS3 (Open-Label Extension \[OLE\] Study) who have completed 205 weeks of treatment.
* Female patients of childbearing potential, and male patients with partners of childbearing potential must be willing to use acceptable contraception, or refrain from sexual activity.

Exclusion Criteria:

* Any patient who is pregnant or plans to become pregnant.
* Any patient who was withdrawn from the ISIS 721744-CS3 OLE study due to a serious adverse event (SAE) related to donidalorsen therapy or who voluntarily withdrew prior to 205 weeks of treatment.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00419848: the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris
Official title: the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Acne
Keywords: Acne
Azithromycin
Doxycycline
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2007-01-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: a comparison of efficacy and adverse side effects occurrence of Doxycycline and Azithromycin in the management of moderate acne vulgaris


Eligibility criteria: Inclusion Criteria:

* Between 18 to 30 year old
* Moderate facial Acne(At least 10 inflammatory lesions with maximum 3 nodules and pseudocysts

Exclusion Criteria:

* Pregnancy
* Breast Feeding
* Acne Fulminant
* Acne conglobate
* Isotretinoin therapy within past 6 months
* topical treatment in last 2 weeks
* use of systemic antibiotic in the last month
* Hyperandrogenism symptoms
* Menstrual irregularity

Primary outcomes:
measure: change in acne lesions
timeFrame: 12 weeks
Secondary outcomes:
measure: global response rates, patient's own assessment, side effects and compliance
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Shaheed Beheshti Medical University, Skin research center
Study officials:
affiliation: Skin Research Center
name: Parviz Toossi, M.D.
role: STUDY_CHAIR
affiliation: Skin Research Center
name: Hamideh Moravvej, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Skin Research Center
name: Akbar Mousazadeh halim, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06815848: Venous Drainage of the Craniocervical Junction: a Retrospective Anatomical Study (SVCR MR1)
Official title: Venous Drainage of the Craniocervical Junction: a Retrospective Anatomical Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Study of Venous Drainage of the Cranio-Cervical Junction Using MRI
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2025-02-10
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from the Brest University Hospital who underwent a cranio-cervical MRI with injected T1 GRE sequence between January 1, 2019, and November 1, 2024.

Brief summary: This study aims to examine the feasibility of distinctly visualizing the different cervical venous networks (subcutaneous, muscular, extra-canalicular, and intra-canalicular) using dedicated magnetic resonance imaging (MRI) sequences. Theoretically, these venous networks contribute to the complex distribution of blood drainage in the cervical region, but their precise identification on imaging remains challenging.The objectives of this research are twofold: first, to assess the ability of MRI to differentiate each venous network, thereby enhancing the anatomical and functional understanding of this region; and second, to explore the possibility of grouping patients according to the predominant venous network, which could reveal significant physiological variations and specific anatomical profiles.The results could not only refine the diagnosis of cervical vascular pathologies but also guide targeted therapeutic approaches.


Eligibility criteria: Inclusion Criteria:

* Patient affiliated with a social security system
* Age \>18 years
* Patient who underwent a T1 Angio-MRI with gradient echo and contrast agent of the cranio-cervical region, regardless of the indication, at the Brest University Hospital between 01/01/2019 and 01/11/2024

Exclusion Criteria:

* Patients under judicial protection (guardianship, curatorship, etc.) Refusal to participate (expressed opposition) History of venous occlusive pathology OR vascular pathology such as cerebral or spinal AVM/FAV History of posterior cranial fossa surgery OR surgical approach to the posterior cervical spine History of radiotherapy/chemotherapy/any known vein-toxic therapies

Primary outcomes:
measure: Number of venous vessel in the four venous networks (subcutaneous, muscular, extra-canal, and intra-canal).
timeFrame: at the time of inclusion
Secondary outcomes:
measure: Number of vessel in each groups
timeFrame: at the time of inclusion
measure: number of vessel on the left and the right in one patient
timeFrame: at the time of inclusion
Other outcomes:
Locations:
city: Brest
country: France
facility: Chu Brest
Study officials:
References:
Clinical trial NCT01899248: The Effect of Inhalation Agent on the QTc Interval During Liver Transplantation: Sub Study (NCT01886664)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anesthesia, General
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2013-07-15
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: subjects who were enrolled prospectively in study (ClinicalTrials.gov Identifier NCT01886664)

Brief summary: The purpose of this study is to assess the effects of inhalation agent on corrected QT interval duration during liver transplantation.


Eligibility criteria: Inclusion Criteria:

* elective liver transplantation

Exclusion Criteria:

* age \< 18, age \> 65
* patient refusal
* re-transplantation

Primary outcomes:
measure: corrected QT interval (QTc interval)
timeFrame: up to postoperative day 1 after surgery
Secondary outcomes:
measure: proportion of patients whose QTc interval is more than 450 ms for men and 470 ms for women
timeFrame: up to postoperative day 1 after surgery
measure: proportion of patients who have more than 500 ms of QTc interval
timeFrame: up to postoperative day 1 after surgery
measure: Tp-e interval
timeFrame: up to postoperative day 1 after surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
Clinical trial NCT01140048: Respiratory Syncytial Virus (RSV) Follow-Up Study (MK-0476-374)
Official title: An Observational Follow-Up Study of Pediatric Patients Who Participated in a Previous Respiratory Syncytial Virus (RSV)-Induced Bronchiolitis Study of Montelukast
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory Syncytial Virus Bronchiolitis
Keywords: Asthma
Lead sponsor: Organon and Co
Sponsor class: INDUSTRY
First posted: 2010-06-09
Enrollment: 343
Sex: ALL
Minimum age (years): 18
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study sample includes participants who completed all visits of Protocol 272 from approximately 38 study sites worldwide. Participants enrolled in Protocol 272 were 3- to 24-month-old children with their first or second episode of "severe" RSV-induced bronchiolitis.

Brief summary: This is a prospective, multicenter, observational study in participants who completed the 24-week, placebo-controlled MK-0476 Protocol 272 (NCT00076973) study of montelukast in the treatment of respiratory symptoms subsequent to RSV-induced bronchiolitis. The purpose of this study is to better understand the clinical and demographic correlates of asthma and atopic disorders in children (through the age of 6 years) with a history of severe RSV-induced bronchiolitis.


Eligibility criteria: Inclusion Criteria:

* successfully completed MK-0476 Protocol 272
* had RSV-induced bronchiolitis at entry into Protocol 272

Exclusion Criteria:

* had developed or had been diagnosed with any illness or congenital disorder that could be immediately life threatening

Primary outcomes:
measure: Percentage of Participants With Asthma at 6 Years of Age: Overall and by Prognostic Factor
timeFrame: At 6 years of age
Secondary outcomes:
measure: Percentage of Participants With Atopic Disorders at 6 Years of Age: Overall and by Prognostic Factor
timeFrame: At 6 years of age
measure: Percentage of Participants With Use of Chronic Asthma Therapy at 6 Years of Age: Overall and by Prognostic Factor
timeFrame: At 6 years of age
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Lu S, Hartert TV, Everard ML, Giezek H, Nelsen L, Mehta A, Patel H, Knorr B, Reiss TF. Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood. Pediatr Pulmonol. 2016 Dec;51(12):1382-1392. doi: 10.1002/ppul.23461. Epub 2016 May 6.